Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshner’s duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and
Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshners duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and president of Trex subsidiary Lorad (SCAN 5/12/99).
Under Kirshners chairmanship, TransScan received premarket approval clearance from the Food and Drug Administration for improvements in the design and operation of its TS-2000 electrical impedance breast scanning system (SCAN 11/24/99). The FDA initially cleared the unit last April for use as an adjunct to mammography for follow-up exams in patients with equivocal mammograms.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.